Orthotopic liver transplantation using low‐dose tacrolimus and sirolimus
Vivian C. McAlister, Kevork M. Peltekian, Dickran A. Malatjalian, Shannon Colohan, Sara MacDonald, Hinrich Bitter‐Suermann, Allan S. MacDonald – 30 December 2003 – Although sirolimus (SRL) binds the immunophilin FK506‐binding protein‐12 (FKBP‐12) with greater avidity than tacrolimus (TAC), animal studies have shown that SRL and TAC act synergistically to prevent rejection. Dose‐related toxicity is more often the cause of TAC discontinuation than rejection.